UnitedHealth Group Incorporated $UNH Stock Holdings Lifted by University of Texas Texas AM Investment Management Co.

Key Points

• University of Texas Texas AM Investment Management Co. sharply increased its UnitedHealth stake by 4,490.5% in Q3, to 21,805 shares valued at about $8 million. Institutional investors collectively own 87.86% of the company.
• UnitedHealth reported quarterly EPS of $4.69, beating the $4.14 consensus, and revenue of $112.72 billion, above estimates; revenue was down 0.4% year over year.
• Analysts’ consensus rating is “Moderate Buy”, with a $463.93 average price target. The company also declared a $2.32 quarterly dividend, equivalent to a stated 2.4% yield.

University of Texas Texas AM Investment Management Co. increased its stake in UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 4,490.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,805 shares of the healthcare conglomerate's stock after buying an additional 21,330 shares during the quarter. UnitedHealth Group comprises 1.0% of University of Texas Texas AM Investment Management Co.'s portfolio, making the stock its 21st largest position. University of Texas Texas AM Investment Management Co.'s holdings in UnitedHealth Group were worth $8,004,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. General Partner Inc. purchased a new position in shares of UnitedHealth Group in the third quarter valued at $512,000. PBCay One RSC Ltd purchased a new stake in UnitedHealth Group during the 1st quarter worth $14,343,000. Lee Johnson Capital Management LLC acquired a new position in UnitedHealth Group in the 2nd quarter worth $6,180,000. Kinsale Capital Group Inc. lifted its holdings in UnitedHealth Group by 13.4% in the 2nd quarter. Kinsale Capital Group Inc. now owns 38,510 shares of the healthcare conglomerate's stock worth $16,006,000 after buying an additional 4,557 shares in the last quarter. Finally, Kelleher Financial Advisors boosted its position in UnitedHealth Group by 135.9% in the 2nd quarter. Kelleher Financial Advisors now owns 5,495 shares of the healthcare conglomerate's stock valued at $2,284,000 after buying an additional 3,166 shares during the last quarter. 87.86% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other UnitedHealth Group news, CEO Patrick Conway sold 1,169 shares of UnitedHealth Group stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $390.00, for a total value of $455,910.00. Following the completion of the transaction, the chief executive officer directly owned 15,328 shares in the company, valued at $5,977,920. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.19% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on UNH. Wall Street Zen raised UnitedHealth Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Jefferies Financial Group increased their price target on UnitedHealth Group from $401.00 to $490.00 and gave the company a "buy" rating in a report on Friday, July 17th. KeyCorp restated an "overweight" rating on shares of UnitedHealth Group in a research note on Wednesday, October 14th. Morgan Stanley lifted their price target on UnitedHealth Group from $529.00 to $531.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 27th. Finally, Mizuho upped their price objective on UnitedHealth Group from $493.00 to $500.00 and gave the company an "outperform" rating in a research note on Thursday, October 22nd. Twenty analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $463.93.

UnitedHealth Group Stock Down 0.0%

UNH stock opened at $394.14 on Monday. The firm has a market cap of $353.16 billion, a price-to-earnings ratio of 22.51, a PEG ratio of 1.43 and a beta of 0.51. UnitedHealth Group Incorporated has a 1-year low of $255.96 and a 1-year high of $461.62. The firm has a fifty day moving average price of $390.62 and a two-hundred day moving average price of $364.03. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.74 and a quick ratio of 0.74.

UnitedHealth Group (NYSE:UNH - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The healthcare conglomerate reported $4.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.14 by $0.55. UnitedHealth Group had a net margin of 3.53% and a return on equity of 17.95%. The company had revenue of $112.72 billion for the quarter, compared to the consensus estimate of $111.31 billion. During the same period last year, the firm posted $2.59 EPS. The company's revenue for the quarter was down .4% on a year-over-year basis. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. Research analysts predict that UnitedHealth Group Incorporated will post 20.61 EPS for the current year.

UnitedHealth Group Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Shareholders of record on Monday, December 7th will be issued a $2.32 dividend. The ex-dividend date of this dividend is Monday, December 7th. This represents a $9.28 dividend on an annualized basis and a yield of 2.4%. UnitedHealth Group's dividend payout ratio (DPR) is currently 53.00%.

Trending Headlines about UnitedHealth Group

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: ETFs purchased $56.4 million of UNH shares on Nov. 4, a potentially supportive demand signal. ETFs Are Buying UnitedHealth (UNH) on Nov. 4
• Positive Sentiment: UnitedHealth’s Q3 adjusted EPS of $4.69 topped analyst expectations, and a recent earnings analysis said the results bolstered confidence in a margin recovery. UnitedHealth (UNH) Q3 Earnings Lift Confidence In Margin Recovery
• Positive Sentiment: A Zacks article characterized Wall Street analysts’ view of UNH as a Buy, offering a favorable sentiment signal, though the article summary did not cite a specific new rating change. Wall Street Analysts See UnitedHealth (UNH) as a Buy: Should You Invest?
• Positive Sentiment: The company declared a quarterly dividend of $2.32 per share, equivalent to $9.28 annually and a reported yield of 2.3%. UnitedHealth Group Declares Quarterly Dividend Of $2.32 Per Share
• Negative Sentiment: Utilization and policy concerns remain an overhang for the company, highlighting uncertainty around medical costs and the regulatory environment. Utilization and Policy Concerns Weigh on UnitedHealth Group Incorporated (UNH)
• Negative Sentiment: Renewed calls for a regulatory review of UnitedHealth’s business scale, alongside warnings that AI could disrupt large healthcare companies, add longer-term risk concerns. UnitedHealth Group (UNH) Draws Breakup Pressure As AI Threat Enters The Story

UnitedHealth Group Company Profile

UnitedHealth Group is a diversified health care company that provides health benefits and health services through two main businesses: UnitedHealthcare and Optum. UnitedHealthcare offers health insurance and related benefit plans to individuals, employers and government programs, including Medicare and Medicaid.

Optum provides services across the health care system, including care delivery, pharmacy services, pharmacy benefit management, health technology and data analytics. Its businesses serve consumers, health care providers, employers, health plans and government organizations.

Founded in 1977 as United HealthCare Corporation, the company is headquartered in Minnetonka, Minnesota.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.